View all dosages and compare prices:
Buy Retatrutide — all dosages →
Retatrutide 40 mg
ALLUVI · Triple agonist
Next-generation triple agonist · 40 mg pen · ALLUVI Healthcare
40 mgShips today · before 19:00
Delivery Sat, Jun 27 · Nova Poshta
Retatrutide 40 mg by ALLUVI Healthcare — injection pen with triple agonist GLP-1/GIP/glucagon. 4 full doses of 10 mg (40 mg total), 12 needles included, dosing instructions.
Specialist support included in the price
A personal DOZA specialist guides you throughout the entire course — from first consultation to results.
Triple agonist — next generation
Retatrutide — a triple GLP-1/GIP/glucagon agonist. Investigational Phase 3 molecule by Eli Lilly. Not approved by FDA/EMA.
Manufacturer: ALLUVI
ALLUVI — a brand of peptide products for metabolic correction programs. Manufacturing meets GMP standards.
Free consultation
Benefits
- ✓Triple mechanism of action — only GLP-1 + GIP + glucagon agonist
- ✓40 mg in pen — 4 full doses of 10 mg (up to 16 weeks with gradual escalation)
- ✓12 needles included + ALLUVI dosing instructions
- ✓Isotonic solution, pH 6.5–7.5 — comfortable injection
- ✓Up to 24% weight loss over 48 weeks (Phase 2 study, NEJM 2023)
- ✓Cold chain delivery with cooling elements (2–8°C) across Ukraine
- ✓Free 24/7 DOZA specialist support throughout the entire course
Retatrutide 40 mg (ALLUVI) — detailed description
Retatrutide by ALLUVI Healthcare — the world's first triple agonist targeting GLP-1, GIP and glucagon receptors in a convenient injection pen.
Each full dose contains 10 mg of retatrutide, with a total of 40 mg active ingredient in the pen. The pen allows dosing from 2.5 mg to 10 mg using the dial mechanism.
Dosing schedule per ALLUVI instructions:
• Weeks 1–4 (starting dose): 2.5 mg once weekly
• Weeks 5–8: 5 mg once weekly
• Weeks 9–13: 7.5 mg once weekly
• Weeks 14+: 10 mg once weekly
Do not increase dose until hunger sensation returns. Important to maintain balanced nutrition throughout the course.
How it works — mechanism of action
Retatrutide is the only triple agonist GLP-1 + GIP + glucagon. Acts on three receptors simultaneously:
1. GLP-1 — reduces appetite, slows gastric emptying, regulates glucose levels.
2. GIP — enhances GLP-1 effects and improves fat tissue metabolism.
3. Glucagon — activates lipolysis (fat breakdown) and thermogenesis (calorie burning).
In Phase 2 clinical trial (NEJM, 2023), participants on 12 mg dose lost up to 24% body weight over 48 weeks — the best result among all weight loss medications.
Dosage
Starting dose: 2.5 mg once weekly (weeks 1–4)
Weeks 5–8: 5 mg once weekly
Weeks 9–13: 7.5 mg once weekly
Weeks 14+: 10 mg (full dose) once weekly
Subcutaneous injection in abdomen, thigh or shoulder area. Same day each week. Do not increase dose until hunger sensation returns.
What's in the kit
Шприц-ручка ALLUVI Retatrutide з набірним механізмом дозування.
• 1 ручка = 40 мг ретатрутиду (4 повні дози по 10 мг)
• 12 одноразових голок ALLUVI в комплекті
• Інструкція з покроковим дозуванням (Dosage Guide)
• Набірний механізм: від 0 до 10 мг за один оберт
Composition
Діюча речовина: ретатрутид (retatrutide) 10 мг на дозу, 40 мг загалом у ручці.
Допоміжні речовини: натрію хлорид, натрію цитрат, лимонна кислота моногідрат, полісорбат 80, бактеріостатична вода.
Для корекції pH використано хлористоводневу кислоту та/або натрію гідроксид.
Розчин ізотонічний, pH 6.5–7.5.
Storage
Зберігати в холодильнику при температурі 2–8°C. Не заморожувати.
Зберігати ручку в картонній упаковці для захисту від світла.
Після першого використання — утилізувати через 12 тижнів.
Не зберігати з приєднаною голкою.
Тільки для підшкірного введення.
Клінічні дослідження
Retatrutide (LY3437943 40 mg) — потрійний агоніст GLP-1 + GIP + глюкагон Eli Lilly. Phase 3 (TRIUMPH-1, TRIUMPH-2). Очікуване схвалення FDA — 2026–2027. На /research зібрана уся доказова база Phase 2 та статус trials.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial (NEJM 2023)PubMed · 2023
- TRIUMPH-1: Phase 3 study of LY3437943 in adults with obesityClinicalTrials.gov · 2024
Retatrutide is an investigational drug currently in Phase 3 clinical trials. Not approved by FDA, EMA or МОЗ України as of 2026.
View full клінічні дослідження database →Titration protocol to 40 mg (retatrutide (triple GLP-1 / GIP / glucagon agonist))
Starting dose (Phase 3 TRIUMPH)
First increase
Second increase
Maximum studied dose
Injection once weekly (per study protocol), subcutaneous (abdomen, thigh or upper arm). Expected weight loss at 40 mg: ~24% over 48 weeks (Phase 2) (based on clinical studies).
Who is Retatrutide 40 mg for
- Retatrutide is an investigational drug (Phase 3), not yet approved by the FDA/EMA
- Triple GLP-1 / GIP / glucagon agonist — a unique mechanism of action
- For patients for whom single (Ozempic) or dual (Mounjaro) agonists did not deliver enough effect
- Strictly under medical supervision
Retatrutide 40 mg — compared to other doses
- Retatrutide 12 mg showed ~24% weight loss over 48 weeks (Phase 2, NEJM 2023)
- Compared to Mounjaro 15 mg (~22–26%) — a similar effect, but with a triple mechanism
- Key difference: retatrutide activates the glucagon receptor, increasing energy expenditure
- No final Phase 3 results yet — efficacy and safety are still being confirmed
FAQ about Retatrutide 40 mg (ALLUVI)
1 ALLUVI Retatrutide injection pen (40 mg total, dial mechanism up to 10 mg per dose), 12 single-use ALLUVI needles and dosing instructions (Dosage Guide) with step-by-step schedule from 2.5 mg to 10 mg.
Anastasia Shapoval
Metabolic Programs and Weight Control Specialist
Other Retatrutide dosages
DOZA client reviews for Retatrutide 40 mg (ALLUVI)
Retatrutide 40 mg (ALLUVI) — noticeable results in just 3 weeks. Cold chain delivery, everything neat. Thank you, DOZA!
Ordering Retatrutide 40 mg (ALLUVI) via DOZA — fast delivery across Ukraine. Consultant helped choose the right dose. Triple agonist works more effectively.
All client results →
Before/after photos · numbers · timelines · reviews
Other Retatrutide dosages
Buy Retatrutide 40 mg in Ukraine
Buy Retatrutide 40 mg (ALLUVI) — next-generation triple GLP-1/GIP/glucagon agonist from DOZA. Next-generation triple agonist · 40 mg pen · ALLUVI Healthcare. Dosage 40 mg — for optimal therapeutic effect. Order via DOZA online service, delivery 1–2 days.
Retatrutide 40 mg (ALLUVI) price — 18 000 ₴.Cold chain delivery in thermal box.
Free DOZA specialist consultation. Available 24/7.
Buy Retatrutide 40 mg (ALLUVI) in Ukraine — DOZA online service with delivery in 1–2 days. Specialist consultation included.
⚠️ Retatrutide is an investigational product currently undergoing Phase 3 clinical trials. Results may vary. Consult a specialist before starting the program. Retatrutide is currently undergoing large-scale Phase 3 clinical trials (the TRIUMPH program). Final regulatory approval is expected after the completion of trials.